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Abstract
Background: Myocardial infarction remains as a major cause of mortality worldwide and a high
rate of survivors develop heart failure as a sequel, resulting in a high morbidity and elevated
expenditures for health system resources. We have designed a multicenter trial to test for the
efficacy of autologous bone marrow (ABM) mononuclear cell (MC) transplantation in this subgroup
of patients. The main hypothesis to be tested is that treated patients will have a significantly higher
ejection fraction (EF) improvement after 6 months than controls.
Methods:  A sample of 300 patients admitted with ST elevation acute myocardial infarction
(STEMI) and left ventricle (LV) systolic dysfunction, and submitted to successful mechanical or
chemical recanalization of the infarct-related coronary artery will be selected for inclusion and
randomized to either treated or control group in a double blind manner. The former group will
receive 100 × 106 MC suspended in saline with 5% autologous serum in the culprit vessel, while the
latter will receive placebo (saline with 5% autologous serum).
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Implications: Many phase I/II clinical trials using cell therapy for STEMI have been reported,
demonstrating that cell transplantation is safe and may lead to better preserved LV function.
Patients with high risk to develop systolic dysfunction have the potential to benefit more. Larger
randomized, double blind and controlled trials to test for the efficacy of cell therapies in patients
with high risk for developing heart failure are required.
Trial Register: This trial is registered at the NIH registry under the number NCT00350766.
Background
Acute myocardial infarction (AMI) is a major cause of
mortality worldwide. Many survivors of AMI develop
heart failure, associated with a high morbidity that wors-
ens their quality of life and generates elevated expendi-
tures for health system resources.[1].
Heart Failure (HF), which has ischemic cardiomyopathy
as its most frequent cause, is an epidemic disease of this
century. It affects from 2 to 4 million people in the United
States (US), and 15 million people around the world.[2]
HF in Brazil generates more than 260.000 hospitaliza-
tions per year, representing the fourth major cause of hos-
pitalization (2.60% of all hospitalizations in 2007) with
an in hospital mortality of 8.1%.[3].
Different medical therapies are efficient for patients who
develop systolic dysfunction after AMI, as ACE inhibitors
and beta blockers, which aim to improve the infarct
repairing response. Recently, cell therapy has appeared as
a new perspective. Growing evidence suggests benefits of
cell therapies in repair or regeneration the myocardium,
and several types of cells have been used. However, cellu-
lar and molecular mechanisms responsible for the ven-
tricular function improvements, which have been
reported in most of the studies, are still poorly under-
stood. Among other questions, the best pathway to intro-
duce stem cells into the heart has been investigated for the
treatment of ischemic cardiomyopathy.
To our knowledge, five other clinical trials of autologous
bone marrow (ABM) mononuclear cell (MC) transplanta-
tion through intracoronary injection after AMI were pub-
lished, with more than 300 patients tested and followed
for at least 1 year. [4-10] Importantly, no adverse effects
associated to the injection procedure were reported.
Even though these are still preliminary data, the results
have led us to investigate cell therapy as an alternative
treatment of ischemic cardiomyopathy following acute
myocardial infarction.
Hypothesis
The main hypothesis of this trial is that patients submitted
to autologous bone marrow stem cell transplantation will
present, on average, at least 5% higher EF in comparison
with the placebo group after 6 months follow up.
Methods
This research protocol integrates the Multicenter Rand-
omized Trial of Cell Therapy in Cardiopathies (MiHeart
Study) which has been already published.[11] MiHeart
Study is divided in four main branches: Dilated Cardio-
myopathy; Chagas Disease; Chronic Ischemic Cardiomy-
opathy and Acute Myocardial Infarction. Here we detail
the protocol of the Acute Ischemic Cardiomyopathy
branch which was approved by the Institutional Review
Board/Ethics Committee at each center including the
Anchor Center (PROCEP, Rio de Janeiro) and by the Bra-
zilian National Ethics Council for Human Research
(CONEP, Brasilia) in accordance with the principles out-
lined in the Declaration of Helsinki and National Health
Council Resolution n° 196/96.
Study design
Multicenter, double blind, randomized and placebo con-
trolled trial.
Population and enrollment
Three hundred patients with ST elevation AMI (STEMI)
submitted to successful mechanical (TIMI flow grade 3) or
chemical recanalization of the culprit coronary artery up
to 24 hours after symptoms onset, and presenting EF ≤
50% will be selected for inclusion.
Patients will be eligible if presenting all the following
characteristics: [1] STEMI; [2] age between 30 and 80
years; [3] EF ≤ 50% (Simpson) and [4] regional dysfunc-
tion in the infarct-related area, measured before cells
injection. Among patients submitted to fibrinolytic ther-
apy, the angioplasty of the related artery should be done
up to 72 hours after fibrinolysis. All patients will be
treated with Liberte™ stents, generously donated by Bos-
ton Scientific Corp., Natick, Massachusetts.
Patients will be excluded if presenting any of the follow-
ing: obstruction >50% on Left Main Coronary Artery or
multivessel coronary disease, indicating the need for
CABG (Coronary Arterial Bypass Grafting); coronary anat-
omy presenting no need for angioplasty with stent
implant; final diastolic pressure of left ventricle (LV)Trials 2008, 9:41 http://www.trialsjournal.com/content/9/1/41
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higher than 30 mm Hg during initial ventriculography;
cardiac arrest or Killip IV at admission with the need of
ventilatory support; cardiogenic shock persisting up to the
third day after symptoms onset; mechanical complica-
tions of AMI; significant valve disease; chronic use of
immunosuppressant agents; >2,0 mg/dl creatinine or pre-
vious dialysis treatment; sepsis; sustained ventricular tach-
ycardia after 48 hours post-AMI; illicit drugs abuse or
alcohol abuse (based on DSM IV); myocarditis; active
liver disease; severe COPD (Chronic Obstrutive Pulmo-
nary Disease); hematological disease, neoplasm, bone
disease or haemostatic disturbances; inflammatory dis-
ease or chronicle infectious disease; presence of definitive
implantation of a cardiac pacemaker or cardiac defibrilla-
tor or any co-morbidity, with survival impact in 2 years.
Patients will be included only after signing Informed Con-
sent form, written in accessible language and with infor-
mation about all relevant aspects regarding the research
protocol.
Randomization
A computer-random number generator will perform ran-
domization procedure in the day of injection as previ-
ously published in Trials.[11] Briefly, software was created
in R version 1.9.0 to specifically generate the randomiza-
tion sequence for the study. It is known that a simple ran-
domization is sufficient and efficient to render the study
groups homogeneous for known and unknown factors in
large scale clinical trials. To insure homogeneity in the
two arms of the study we adopted block randomization.
We will use randomization by variable size block (blocks
of 2, 4 or 6 patients). Patients will be randomized after
bone marrow aspiration and only the hematologist
responsible for cell separation will have the login and
password to randomize the patient online. According to
the assigned group, darkened syringes containing the
mononuclear cell fraction or saline with 5% autologous
serum will be then prepared and sent for injection.
Cell transplantation Phase
✓ Bone marrow aspiration procedure
About 100 ml of bone marrow aspirate will be harvested
from iliac crest between the 5th and 7th day after myocar-
dial reperfusion therapy under local anesthesia and seda-
tion at an intensive care unit or surgical center. The
aspiration procedure will be done by using a 1.8 mm Jam-
shidi needle.
ABMMC will be isolated by density gradient centrifuga-
tion on Ficoll- Paque™ plus® (Amersham Biosciences) and
manipulated under aseptic conditions. 100 × 106 cells will
be resuspended in 10 ml saline solution with 5% autolo-
gous serum and filtered through 100 μm nylon mesh to
remove cell aggregates for injection. A fraction of the cell
suspension will be used for cell counting and viability
testing with trypan blue exclusion. Cell viability must be
above 90% to be injected. Post-hoc characterization of
leukocyte differentiation markers by flow cytometry
(table 1) and functional assays will be done on another
fraction of cells. This last evaluation concerns clonogenic
capacity of marrow progenitors by colony-forming assays
(granulocyte-macrophage colony-forming units – CFU-
GM, vascular-endothelial cell colony-forming unit – CFU-
VE, and fibroblast colony-forming assay – CFU-F), as pre-
viously described.[12,13]
An out of hospital independent team at each site, com-
posed by 2 biologists trained by the anchor center, will be
the responsible for cell separation and preparation of the
solution according to the randomization result. Control
group will receive a placebo saline solution containing
autologous blood serum and treated group will receive a
saline solution containing ABMMC. The solutions con-
taining cells or placebo will be placed in opaque syringes
(covered in 50% insulfilm), reinforcing the blind applica-
tion, for injection.
In order to guarantee the quality of the material, imu-
nophenotyping and clonogenic capacity analysis will be
all done at a Core Lab as detailed in the appendix [see
Additional file 1]. Cells will be kept in appropriate condi-
tions and sent to the cells core lab for these analyses.
Exceeding material and cells collected from patients in the
placebo group will be stored, duly frozen, until the end of
the trial.
Bone marrow collected from patients included in control
group will be used for phenotyping and cell analysis,
which will be correlated with patients' clinical evolution.
Cell transplantation
Cell delivery is predicted to be performed about 6 hours
after bone marrow cell harvesting. Arterial accesses will be
performed using femoral or radial approach. All patients
will receive 10,000 IU of heparin IV after sheet insertion.
When non-infarct related vessel intervention is planned, it
will be performed before cell transfer. Electrocardiogra-
phy, pulse oximetry, and vitalsigns will be monitored
throughout the procedure, as well as symptoms.
A 6-F guiding catheter will be placed at the ostium of the
infarct-related coronary artery. After positioning the cath-
eter inside the coronary ostium, a dosage of isossorbide
mononitrate will be administered (total of 1 ml = 10 mg).
Then, a coronary will be performed in a calibrated system
in order to visualize the coronary blood flow before injec-
tion. At least one projection for evaluating "TIMI frameTrials 2008, 9:41 http://www.trialsjournal.com/content/9/1/41
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count" will be performed with a 30 frame/sec filming,
attempting to visualize the distal coronary bed.
After TIMI 3 flow scrutiny, an over-the-wire (OTW) bal-
loon catheter (Maverick® Over-The-Wire balloon, Boston
Scientific, Natick, MA, USA) will be positioned inside the
previously implanted stent in the culprit vessel to tran-
siently interrupt anterograde blood flow during infusions
through a stop-flow technique. The use of the over-the-wire
balloon with over 0.5 mm of the reference lumen diame-
ter in a low pressure (< 4ATM) is recommended. The ideal
balloon extent is 9 mm, limited to the edge of the previ-
ously implanted stent.
Cells solution will be infused through the central lumen
of the balloon catheter, in about 40 seconds, during 3 cor-
onary occlusions, each lasting 2 – 3 minutes, followed by
2 minutes of balloon deflation.
A final coronary angiography will be performed at the end
of all procedures as control in order to ascertain TIMI
frame count pre and post PCI and cell transfer.
✓ Baseline exams (before bone marrow aspiration) and follow up
The chronogram of the study is shown in table 2. Briefly,
patients will be submitted to a clinical evaluation at hos-
pital admission and clinical data regarding blood pres-
sure, heart rate and Killip and Kimball classification will
be stored. Patients will be standardly treated with chemi-
cal or mechanical reperfusion according to the local center
availability. A coronary angiography and an invasive ven-
triculography will be performed in all patients before
angioplasty in order to evaluate inclusion/exclusion crite-
ria. Patients submitted to fibrinolysis must have the angi-
oplasty of the infarct-related coronary artery performed up
to 48 hours after reperfusion. Laboratorial dosage will be
also performed as shown in table 2.
Three to five days after reperfusion therapy (mechanical or
chemical), patients will be submitted to another clinical
evaluation, including an EKG, an echocardiogram and
laboratory tests, from which results will be used as base-
line data for the research protocol, before injection proce-
dure. A new CK-MB mass and troponin dosage will be
performed in the morning preceding the injection proce-
dure and timely in the 24 hours following the injection.
Table 1: Post-hoc characterization of leukocyte differentiation markers
Phenotype Intended designation
1. CD45loCD34+ ISHAGE protocol
2. Lin-CD45loCD34+ Hematopoietic progenitors
3. Lin-CD45loCD34+CD133+CD117+ Hematopoietic stem cells*
4. Lin-CD45-CD133+CD31+CD144+KDR+ Endothelial precursor*
5. Lin-CD45-CD133-CD31+CD144+KDR+ Endothelial cell*
6. CD45+CD10+CD33+HLA-DR-CD45RA- Myeloid precursor*
7. CD45+CD10+CD33-HLA-DR+CD45RA+ Lymphoid precursor*
8. CD45-CD133+CD146+CD144+CD166+ Mesenchymal progenitor*
9. CD45-CD133-CD146+CD73+CD166+ Mesenchymal cell*
10. CD45+CD10+CD34+CD19-CD38-TdT+IgM- pre-pro-B intermediary
10.1. CD45+CD10+CD34+CD19+CD38-TdT+IgM- pro-B/pre-B I intermediary
10.2. CD45+CD10+CD34-CD19+CD38-TdT-IgM- Pre-B II intermediary
10.3. CD45+CD10-CD34-CD19+CD38+TdT-IgM+CD24hi Immature B LΦ
10.4. CD45+CD10-CD34-CD19+CD38+TdT-IgM+ Naïve B LΦ
10.5. CD45+CD10-CD34-CD19+CD38+TdT-IgM+CD24loCD69+ Mature B LΦ
11. CD45+CD34+CD38-CD1a-CD3-CD4-CD8- LΦ-T DN1
11.1. CD45+CD34+CD38+CD1a-CD3-CD4-CD8- LΦ-T DN2
11.2. CD45+CD34+CD38+CD1a+CD3-CD4-CD8- LΦ-T DN3
11.3. CD45+CD34+CD38+CD1a+CD3loCD4+CD8- LΦ-T DN4-ISP
11.4. CD45+CD34+CD38+CD3-CD4+CD8+ LΦ-T DP
11.5. CD45+CD34+CD38+CD3+CD4+CD8+ LΦ-T DP-CD3
12. CD45+CD34+CD3+CD4+CD8- LΦ-T CD4
13. CD45+CD34+CD3+CD4-CD8+ LΦ-T CD8
14. CD45+CD122+CD56+CD3- NK cells
15. CD45+CD66acde+ Neutrophils/Basophils
16. CD45+CD41a+ Megakaryocytes
17. CD45+CD66acde-CD41a-CD14+CD16+ Monocytes/Macrophages
*The intended designation to some phenotypes will be more deeply explored with additional markers like CD117, CD31, CD105, CD106, CD166 
and others of interest. Besides, cell subpopulations also will be sorted to perform supplementary function assays.T
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Table 2: Chronogram of the study
Informed Consent 
Randomization 
Exams/Visits After Injection
Baseline pos-
reperfusion
3rd–5th day of 
reperfusion
5th to 7th day Up to 1 h 12 h 24 h 6th to 9th day 1 month 3 months 6 months 1 year
Medical visit    
ALT, AST, AP, PT, 
aPTT and INR

Total Cholesterol, 
LDL-cholesterol, 
HDL-cholesterol 
and Triglycerides

Full blood panel, 
Glucose, Urea, 
Creatinine, Na+, 
K+, CRP
  
CK-MB mass, 
Troponin I
   
Electrocardiogram        
Echocardiogram    
Cardiac MRI 
Coronary 
angiography
 
Cells transplant 
Cells sample storage 
SF-36, Minnesota 
and Seattle QOL
  
QALY Evaluation  
ALT and AST: alanine and aspartate aminotransferases, respectively; AP: alkaline phosphatase; INR: international normatized ratio; PT: prothrombin time; aPTT: activated partial thromboplastin time; 
CRP: C-reactive protein; MRI: magnetic resonance image; QOL: quality of life questionnaires; QALY: quality adjusted life year.Trials 2008, 9:41 http://www.trialsjournal.com/content/9/1/41
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The baseline cardiac magnetic resonance imaging (MRI)
will be performed between day 6 and 9 after the AMI-
related coronary artery recanalization. This exam may be
performed either in the hospital or at a reference hospital.
All imaging exams will be evaluated off line by the core
lab specified in the appendix [see Addition file 1].
Hospital discharge is predicted 24 hours after cell trans-
plantation unless otherwise indicated, making a total
length of stay of approximately 7 days. Patients will be
provided with clopidogrel, aspirin and pravastatin during
the entire study and treated at the discretion of the attend-
ing physician.
Patients will be followed for 1 year after the procedure
according to the chronogram of the study shown in table
2. All imaging exams will be stored and sent to the core lab
for independent analysis as specified in the appendix [see
Addition file 1].
Cardiac MRI will be done by the local centers with com-
mercially available software, electrocardiographic trigger-
ing, and cardiac-phased array coil. LV function will be
assessed by the use of steady-state free-precession gradi-
ent-echo sequence (SSFP). Eight to twelve short axis slices
will be acquired during a 10–15 seconds breath-holding
allowing for coverage of the entire LV. Additionally, 3
long-axis views will also be acquired: 2-chamber and 4-
chamber views and left ventricle out flow tract. Regional
LV function will be assessed by measuring systolic wall
thickening in the infarct region, the adjacent border zone
and remote myocardium and semi-quantitatively
assessed, using a 17-segment model[14].
Transmural extent of late hyper-enhancement within each
segment will be graded according to the following classi-
fication: 0–25%, 26–50%, 51–75%, and more than 75%
hyper-enhancement. Segmental functional recovery is
defined as an increase from hypokinetic to normokinetic,
from akinetic to hypokinetic or normokinetic, or from
dyskinetic to akinetic, hypokinetic, or normokinetic. Inf-
arct size will be measured by planimetry.
Microvascular obstruction will be defined on late
enhanced images taken early (within 2–5 min) after injec-
tion of 0.20 mmol/kg of gadopentetate dimeglumine
(Gd-DTPA), in the LV short and long axis at the same loca-
tions used for cine-MRI–as a dark, subendocardial zone
within the infarct area.
For assessment of global and regional LV function and cal-
culation of LV mass, endocardial and epicardial borders
will be traced in end-diastolic and end-systolic short-axis
slices. LV end-diastolic and end-systolic volumes (LVEDV
and LVESV) will be calculated and indexed to body-sur-
face area. All MRI studies will be independently analyzed
on an off-line workstation, core laboratory as defined in
the appendix [see Additional file 1].
Sample size
Sample size calculation was performed according to the
following assumptions:
▪ Based on Pró-Cardíaco Hospital and InCor's coronary
care databank, after selecting AMI patients Killip I; II or III,
we have concluded that the left ventricle EF presented a
Gaussian distribution with an average of 37.35% and
standard deviation of 7.9%).
▪ An expert panel has evaluated that an improvement of
+5% (relative gain of +15.9%) on the EF would represent
a significant clinical improvement for the patient.
Considering as clinically beneficial a 5% increase in EF%
with a standard deviation of 5%, 143 patients per arm are
needed to detect a significant difference between groups
with 95% confidence and 80% power. Considering a 5%
loss during follow up, we estimated 150 patients per arm.
End points and statiscal analysis
The primary endpoint of this trial is the global left ven-
tricular EF change from baseline to 6 month follow-up.
The following secondary endpoints will be evaluated for
up to 1 year of follow up: major cardiovascular events (all-
cause mortality, acute myocardial infarction, stroke and
hospital admission due to cardiovascular cause); reinter-
vention of the AMI-related artery and of non-related arter-
ies; by MRI regional wall motion, wall thickening, and
volume of late contrast enhancement; quality of life
assessment using the Short-Form 36, Minnesota Living
with Heart Failure and Seattle Angina questionnaires;
cost-effectiveness and cost-utility evaluation of ABMMC
implant versus conventional treatment.
All outcomes will be analyzed by intention to treat.
Primary outcome will be analyzed by comparing EF,
measured by MRI, between groups, using student t test or
Mann-Whitney according to the sample distribution. Two
evaluations are programmed:
1. Interim analysis, which will use data related to patients
1 to 150;
2. Final analysis, which will use data related to all 300
patients.
Secondary outcomes will only be evaluated after the main
final analyses. Mortality and functional class improve-Trials 2008, 9:41 http://www.trialsjournal.com/content/9/1/41
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ment will be analyzed by non-corrected chi-square test.
Continuous variables with normal distribution will be
analyzed by t student test and ANOVA for repeated meas-
ures. Continuous variables with asymmetric distribution
and quality of life scores will be analyzed by Mann-Whit-
ney test and ANOVA for repeated measures.
The frequency of serious adverse events (which brings
eminent risk of death or permanent disability) will be
analyzed by chi-square or Fisher's test.
The trial can be interrupted after interim analysis; using
the O'Brien and Fleming rule for two sequential tests and
the 5%, in which the null hypothesis is rejected if:
￿ p ≤ 0,0050 in the first analysis;
￿ p ≤ 0.04806 in the final analysis.
Study organization and monitoring
The MiHeart trial is supervised by an executive committee
and coordinated by a study coordination committee.
Members of both committees are listed in the appendix
[see Additional file 1]. The steering committee is respon-
sible for design and conduct of the study. An independent
data and safety monitoring committee monitors the
patient safety as the study progresses. Data will be stored
at both a CRF and at a central database through e-CRF ful-
fillment as previously published, and used as tools for
data monitoring by comparing with the original
reports.[11].
Current status
The names of all participating centers and their represent-
atives are provided in the appendix [see Additional file 1].
Recruitment commenced in August 2006 and is expected
to be completed in August 2009. Analysis and reporting is
to be completed by August 2010.
Discussion
Stem cell therapy still remains as a promising modality to
occupy a real gap of conventional AMI therapy, especially
when this acute event is followed by LV remodeling and
chronic heart failure. There is increasing evidence that
stem cells contribute to the regeneration of cardiac tissue
as a natural healing process following STEMI, thus open-
ing new possibilities for the treatment of this condition.
The safety of ABMMC intracoronary transplantation after
AMI has been shown previously and although data sup-
porting the improvement of ventricular function are con-
flictant, [15-17] the preliminary results regarding regional
contractility and infarct size of most of these studies are
promising.[5,8,15,17,18] Additionally, it should be noted
that many patients included in these trials had preserved
ventricular function, thus encompassing the subgroup
most unlikely to benefit from cell therapy.
As demonstrated in the REPAIR AMI trial, [5] patients
with the worst EFs show greater benefit from cell trans-
plantation. Even though these analyses were underpow-
ered to draw meaningful conclusions about degree of EF
impairment at baseline and follow up and timing of injec-
tions, these initial clinical trials have shown major cardio-
vascular adverse events reduction at 1 year in patients
submitted to intracoronary infusion of ABMMC,[19]
encouraging further phase III trials.
Nevertheless, the current evidence is insufficient to prove
that BM cell therapy after an acute MI can provide addi-
tional beneficial effects on LV function beyond those
achieved by early reperfusion therapy.
Therefore, we have designed a randomized large placebo-
controlled trial, to inject ABMMC using the intracoronary
route in patients with left ventricular dysfunction follow-
ing AMI who were successfully treated with either chemi-
cal or mechanical reperfusion. The purpose of this study is
to test for additional benefits of stem-cell therapy in this
scenario where patients have ventricular dysfunction due
to irreversible myocardial damage. If this assumption
proves to be correct stem cell therapy will be a valid strat-
egy for treating this obscure and harmful condition,
reducing morbidity, mortality, heart transplantation indi-
cation, costs of the treatment and improving life quality.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HD is the PI of this study and AC is the study coordinator.
All authors contributed to the development of the proto-
col and were involved in the writing of the manuscript.
Additional material
Acknowledgements
We gratefully acknowledge the participation of Ana Cristina Reis, Rosalia 
Martinez, Luiza Radespiel, Claudia R. C. Rangel and Mariana E. Souza for the 
outstanding organization of this project.
Additional file 1
Appendix. The data provided describes all committees involved in the coor-
dination of this study, as well as core lab and collaborating centers mem-
bers.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
6215-9-41-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Trials 2008, 9:41 http://www.trialsjournal.com/content/9/1/41
Page 8 of 8
(page number not for citation purposes)
This study was supported by the Brazilian Ministry of Science and Technol-
ogy (MCT)/The Financing Agency for Studies and Projects (FINEP).
References
1. Wu AH, Parsons L, Every NR, Bates ER: J Am Coll Cardiol 2002,
40:1389-94.
2. McMurray JJ, Stewart S: Heart 2000, 83:596-602.
3. Morbidade Hospitalar do SUS – Por Local de Internação –
Brasil  2007 [http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/
miuf.def]. cited 2008 Feb 26
4. Strauer BE, Brehm M, Zeus T, Gattermann N, Hernandez A, Sorg RV,
Kogler G, Wernet P: Dtsch Med Wochenschr 2001, 126:932-938.
5. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N,
Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S,
Zeiher AM: Circulation 2002, 106:3009-17.
6. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C,
Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher
AM: J Am Coll Cardiol 2004, 44:1690-9.
7. Dobert N, Britten M, Assmus B, Berner U, Menzel C, Lehmann R,
Hamscho N, Schachinger V, Dimmeler S, Zeiher AM, Grunwald F: Eur
J Nucl Med Mol Imaging 2004, 31:1146-51.
8. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Brei-
denbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L,
Hertenstein B, Ganser A, Drexler H: Lancet 2004, 364:141-8.
9. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua
RZ, Liao LM, Lin S, Sun JP: Am J Cardiol 2004, 94:92-5.
10. Ruan W, Pan CZ, Huang GQ, Li YL, Ge JB, Shu XH: Chin Med J (Engl)
2005, 118:1175-81.
11. Tura BR, Martino HF, Gowdak LH, Dos Santos RR, Dohmann HF,
Krieger JE, Feitosa G, Vilas-Boas F, Oliveira SA, Silva SA, Bozza AZ,
Borojevic R, de Carvalho AC: Trials 2007, 8:2.
12. Coutinho LH, Gilleece MH, De Wynter EA, et al.: Haemopoiesis: A
Practical Approach Edited by: Testa NG, Molineux G. Oxford Univer-
sity Press, New York; 1993:84-85. 
13. Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiar-
ieri D, McKenzie S, Broxmeyer HE, Moore MA: Blood 1980,
56:289-301.
14. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey
WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS: Circulation 2002,
105:539-42.
15. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet
W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers
F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts
J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F: Lancet
2006, 367:113-21.
16. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T,
Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud
E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Rag-
narsson A, Brinchmann JE, Forfang K: N Engl J Med 2006,
355:1199-209.
17. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV,
Kogler G, Wernet P: Circulation 2002, 106:1913-8.
18. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bru-
yne B, De Bondt P, Van Haute I, Lootens N, Heyndrickx G, Wijns W:
Circulation 2005, 112:I178-83.
19. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R,
Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck
T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B,
Tonn T, Dimmeler S, Zeiher AM: Eur Heart J 2006, 27:2775-83.